Skip to main content

CDXC

Stock
Health Care
Biotechnology

Performance overview

CDXC Price
Price Chart

Forward-looking statistics

Beta
1.23
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

Company info

SectorHealth Care
IndustryBiotechnology
Employees115
Market cap$241.7M

Fundamentals

Enterprise value$561.2M
Revenue$99.6M
Revenue per employee
Profit margin8.58%
Debt to equity5.75

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.11
Dividend per share
Revenue per share$1.31
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$13M
Put-call ratio

Macro factor sensitivity

Growth+5.7
Credit-1.6
Liquidity-0.6
Inflation+3.7
Commodities+0.3
Interest Rates-3.2

Valuation

Dividend yield0.00%
PEG Ratio65.58
Price to sales6.14
P/E Ratio65.58
Enterprise Value to Revenue5.63
Price to book13.23

Upcoming events

Next earnings dayNovember 1, 2024
Next dividend day
Ex. dividend day

News

ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates

ChromaDex (CDXC) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.

Zacks Investment Research (March 4, 2025)
ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

ChromaDex Corp (NASDAQ: CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited.  ChromaDex Asia is expected to assume the distribution agreement with Sinopharm Xingsha relating to the commercialization of Tru.

Benzinga (May 20, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free